August 23, 2017
The health ministry’s key reimbursement panel on August 23 gave its blessing to Biogen Japan’s spinal muscular atrophy (SMA) treatment Spinraza (nusinersen), with an NHI price of 9.32 million yen, and six other drugs for their reimbursement listing on August...read more